Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025)

Arbutus Biopharma's Operating Leases history runs 7 years deep, the most recent figure standing at $199000.0 for Q4 2025.

• In Q4 2025, Operating Leases fell 75.31% year-over-year to $199000.0; the TTM figure through Dec 2025 stood at $199000.0 (down 75.31% YoY), while the FY2025 annual figure was $199000.0, down 75.31% from the prior year.
• Operating Leases came in at $199000.0 for Q4 2025 at Arbutus Biopharma, down from $391000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.5 million in Q1 2021 to a low of $199000.0 in Q4 2025.
• A 5-year average of $1.5 million and a median of $1.6 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases fell 13.67% in 2021 and tumbled 75.31% in 2025, its largest moves.
• Arbutus Biopharma's Operating Leases stood at $2.2 million in 2021, then dropped by 18.65% to $1.8 million in 2022, then retreated by 26.01% to $1.3 million in 2023, then sank by 39.99% to $806000.0 in 2024, then sank by 75.31% to $199000.0 in 2025.
• According to Business Quant data, Operating Leases over the past three periods registered $199000.0, $391000.0, and $575000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison